http://dx.doi.org/10.1590/0037-8682-0087-2013 
INTRODUCTION
Acquired immunodefi ciency syndrome (AIDS) has emerged as a serious public health problem worldwide. From 1981 to June 2011, there were 608,230 cases of AIDS registered in Brazil 1,2 .
The first antiretroviral drug active against human immunodefi ciency virus (HIV) was licensed in 1987, though the initial enthusiasm turned into disappointment with its use as a monotherapy. In contrast, highly active antiretroviral therapy (HAART), which produces a signifi cant attenuation of the viral load, has resulted in important and positive changes in the national public health system with regard to AIDS. In addition, new challenges have arisen with the increased number of people living with AIDS, and new nutritional changes have emerged in this patient population, particularly metabolic changes characterized by hyperglycemia, dyslipidemia, and lipodystrophy 3 , emphasizing the relationship between nutrition and AIDS.
The nutritional approach plays a critical role in the treatment of HIV/AIDS patients. Indeed, a healthy diet increases the levels of cluster of differentiation 4+ (CD4+) lymphocytes, enhances intestinal absorption, and reduces complications caused by diarrhea, muscle loss, lipodystrophy, and any other symptoms that, in one way or another, may be reversed or minimized by a balanced diet 4 .
Foods such as oat bran, soy protein, and fl axseeds improve the lipid profile in hypercholesterolemic individuals and, according to the study performed by Harland, have an additive effect when they are used in combination 5 .
Thus, a diet compound was formulated from these foods with the purpose of helping HIV/AIDS patients control the lipid disorders that result from HAART.
RESULTS

METHODS
Oats are composed of beta-glucans, which are polysaccharides that form part of the soluble portion of dietary fi ber and affect serum cholesterol levels and low-density lipoprotein (LDL) [6] [7] [8] , especially in hypercholesterolemic individuals 9 .
Soy consumption can reduce the risk of metabolic syndrome because of such components as soluble fiber, complex carbohydrates, oligosaccharides, vitamins, minerals, and phytoestrogens, particularly the isofl avones genistein, daidzein, and glycitein 10, 11 . Flaxseed is one of the richest sources of alpha-linolenic acid and lignans, both of which can reduce total cholesterol and LDLcholesterol [12] [13] [14] [15] . In addition to their cholesterol-lowering effect, fl axseed 16, 18 and oat 19 have been reported to cause a regression of the atherosclerosis process in animals.
The present study investigated whether such a formulation would infl uence the lipid profi le of HAART-treated AIDS patients with dyslipidemia, without causing uricemia, as compounds containing soy and grains typically have hyperuricemic effects. All of the patients (n=139) who sought treatment from February 2011 to July 2012 were invited to participate in this study.
However, according to the inclusion criteria, the patients must have been using HAART and presenting with dyslipidemia with or without the use of hypolipidemic medications. Patients with renal failure, pregnant women, and indigenous patients who recently initiated, switched, or stopped the use of HAART or lipid-lowering medications were excluded from this study. A total of 89 patients were included in this research.
Furthermore, the patients who did not regularly use the diet compound and patients who ceased follow-up prior to completing 3 months of monitoring were excluded, resulting in a total sample population of 31 participants.
During the fi rst contact, an informed consent form was signed by each patient after a detailed explanation of the research.
A consultation was then performed to provide nutritional guidance for a low-fat and low-cholesterol diet, and an interview was conducted.
The interview included a structured questionnaire that addressed sociodemographic characteristics, anthropometric measurements (waist-hip ratio, waist circumference, and body mass index (BMI)), and laboratory tests examining total cholesterol, high-density lipoprotein (HDL)-cholesterol, lowdensity lipoprotein (LDL)-cholesterol, triglycerides, and uric acid levels. The data collection was performed before and after 3 months of consumption of the formulation.
The compound was prepared with 1 part fl axseed, 1 part textured soy protein, and 2 parts oat bran, such that 40g (the recommended daily intake for each patient) contained approximately 10g of ground fl axseed, 10g of textured soy protein, and 20g of oat bran. The components were weighed and mixed to homogenize the compound, and the compound was bottled and labeled for distribution.
Each patient received 3 packets containing 1,200g of the compound and was instructed to consume 40g of the product per day using a home measure as a reference. The patients were instructed to consume the product in milk preparations, such as vitamins drinks, porridge, and yogurt, or by adding the compound cooked or uncooked to fruits, soups, and beans in their lunch or dinner meals.
The study evaluated the patients before and after 3 months of consumption, constituting an uncontrolled before and after study.
The variables of total cholesterol, HDL-cholesterol, LDLcholesterol, triglycerides, and uricemia were summarized and represented by the relevant descriptive statistics, including the absolute and relative number, mean, and standard deviation. To compare the laboratory levels before and after the intervention, a t test was used for paired samples, and the Wilcoxon test was used between the 2 groups; a t test was used for independent samples, whereas the Mann-Whitney test was used for 3 groups. An Analysis of Variance or the Kruskal-Wallis test was used after checking the normality of the distribution at a 5% signifi cance level (p-values for two-tailed). The BioEstat version 5.0 program was used.
Ethical considerations
The present study was approved by the Ethics Committee Of the 31 patients, 15 (48.4%) were female, and 16 (51.6%) were male. The patients' ages ranged from 31 to 81 years, with an average age of 50.35 years.
Six (19.4%) patients were followed up with at the outpatient clinic of the Day Hospital/University Hospital-Federal University of Mato Grosso do Sul (HU-UFMS), and 25 (80.7%) patients were followed at CEDIP -Nova Bahia.
When analyzing the results, only the levels of total cholesterol decreased after consuming the formulation for 3 months. The total cholesterol levels decreased from 204.3mg/dL to 200.8mg/dL (a 1.7% decrease), which was not considered to be clinically or statistically signifi cant. The HDL-cholesterol, LDL-cholesterol, and triglyceride levels increased by 4.5%, 1%, and 6.2%, respectively, and uricemia increased by 4.3%. The variations in the laboratory results before and after the study were not signifi cant (Table 1) .
The female patients exhibited no reduction in any of the parameters studied, whereas the males exhibited decreases in total cholesterol (3.8%) and in LDL-cholesterol (0.7%); however, these changes were not signifi cant.
The male patients presented greater uric acid values compared to the female patients, both before and after the intervention ( Table 2) .
All the studied patients were being treated with HAART, and 18 (58.1%) were using medications of the protease inhibitor (PI) class; 13 (41.9%) patients had no PIs in their regimen.
All of the laboratory parameters that were analyzed before the nutritional intervention demonstrated that the patients using PIs exhibited higher values, both for the lipid profi le and the uricemia analysis.
In the group without PIs, there was a decrease in all the lipid profile values (4.5% for total cholesterol, 2.3% for HDL-cholesterol, 2.4% for LDL-cholesterol, and 13.8% for triglycerides) and an increase in uricemia (7.9%). Conversely, in the group using PIs and HAART, all of the study variables increased: total cholesterol by 0.1%, HDL-cholesterol by 6%, LDL-cholesterol by 1.2%, triglycerides by 9.2%, and uric acid by 5.9%. Nonetheless, these variations in the laboratory results before and after the study were not signifi cant (Table 3) .
Before the consumption of the compound, the patients using PIs exhibited higher triglyceride and uric acid values than the patients who were not using PIs; however, after consumption, this was observed for the triglyceride and total cholesterol levels ( Table 3) .
Of the 31 patients, 16 (51.6%) were currently taking lipidlowering medications. There were 4 groups of patients: those who were not using lipid-lowering drugs (48.4%, 15 patients); patients taking only a statin (rosuvastatin) (16.1%, 5 patients); patients taking only a fi brate (ciprofi brate) (12.9%, 4 patients); and patients using a statin and a fi brate (22.6%, 7 patients).
There was no statistically significant difference in the laboratory results before and after compound consumption in the same group or among the groups (Table 4) .
DISCUSSION
The regular consumption of a formulation containing oat bran, soy protein and fl ax seed for 3 months together with individualized dietary guidance did not reduce the lipid levels of the patients; however, it did not contribute to an increase in uricemia. The small number of participants and their heterogeneity, either related to the classes of dyslipidemia or to the type of drugs that they were using, may have limited the investigation of the compound's effect by interfering with the detection power of the statistical tests.
However, all of the participants who completed the data collection during the fi xed period were included in this study.
Nonetheless, the acceptance of this diet by the individual required a new routine, which resulted in many patients leaving the study during the follow-up months.
The follow-up time is an important point to be considered due to the behavioral component of the dietary intervention and the variability between a change in the food consumption level and its impact on metabolic outcomes 20 .
Borodin et al. 21 showed that the duration of interventions must be increased to affect lipid profiles in the general population; indeed, it was observed that the introduction of soy protein for 1 month did not reduce lipid parameters, though it did have a signifi cant effect after 2 months.
The components of the formulation used in this study were fl axseed, soy protein, and oat bran. Triturated fl ax was used because it allows for the absorption of alpha-linolenic acid 22 , a major contributor to the hypolipidemic effect 14, 23 ; furthermore, the antioxidants present in flaxseed act synergistically to enhance the prevention of infl ammatory disorders and heart disease 24 . Molena-Fernandes 25 showed that the consumption of 10g fl axseed and/or 20g per capita of linseed resulted in the rapid elimination of cholesterol, and Couto 26 found a signifi cant reduction in the basal and fi nal serum triglyceride levels (81.8%) of 2 groups of monitored patients who consumed 10g and 20g per capita of triturated fl axseed.
Studies on soy isofl avones have revealed a statistically signifi cant reduction in serum cholesterol levels due to increased LDL receptor activity 27, 28 .
Oat bran has a higher concentration of beta-glucans than other forms of oats 29 , resulting in improved lipid profi les and benefi cial effects on risk factors for heart disease through multiple mechanisms [30] [31] [32] , including immunomodulation and the formation of viscous solutions in the intestine 29 .
However, in our study, there were no statistically signifi cant differences in the levels of total cholesterol, HDL, LDL, triglycerides, or uric acid after the 3 months of consumption of the formulation.
The gender analysis indicated no reduction in lipids after consumption, and, despite the higher uric acid content in the male patients compared to the female patients, there was no increase in the uric acid values before and after the intervention.
It has been observed that higher uric acid levels in women is a risk factor for heart disease 33 .
Before the consumption of the compound, the patients using PIs had higher triglyceride and uric acid values than the patients not using PIs, and this was observed for triglycerides and total cholesterol following the intervention. However, within the same group, there was neither a reduction in lipids nor an increase in uric acid after the intervention. These data are in agreement with studies that demonstrate that lipid abnormalities are more evident among HIV-infected patients after the introduction of HAART [34] [35] [36] [37] , and signifi cantly higher increases in lipids were observed when P Is were added to the antiretroviral scheme 38, 39 . Therefore, it was observed that the compound employed did not provoke a signifi cant change in the lipid profi le of the study population during 3 months of dietary intervention.
Although there was no difference in the observed lipid values after the intervention when the results were stratifi ed according to the use of hypolipidemic drugs, it is possible be that the sample size was not large enough to establish differences between the hypolipidemic agents.
The present study demonstrated that there were minor and insignifi cant variations in uricemia following the use of the formulation. The compound used contained soybeans in the form of textured protein, which is the most concentrated form of the food 40 ; however, soybeans are commonly implicated in high uric acid levels [41] [42] [43] . Nonetheless, Messina and Chan 44 conducted a review of soy foods and hyperuricemia and found no evidence of increased uricemia related to soy intake.
The regular consumption (for 3 months) of a feed compound containing oat bran, textured soy protein, and triturated ground fl axseed together with the individualized dietary guidance did not reduce lipid levels; however, the compound did not contribute to increased uricemia in the study group.
When the results were stratifi ed according to the antiretroviral scheme of the patients, those using PIs showed higher triglyceride and total cholesterol values after the consumption of the compound compared to those who did not use PIs.
This occurrence is most likely due to the strong impact of PIs on the lipid metabolism of these patients.
Further studies with a larger number of participants and higher doses of the components of the compound should be encouraged, particularly addressing patients who are being treated with HAART therapeutic schemes, to investigate whether the compound can positively infl uence the lipid profi le of these patients.
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